Evidence map›Paper›PMID 41530181›Full record

ArticleNPJ vaccines2026

Transfer of breast milk IgA to infants after oral bivalent norovirus vaccination of post-partum women.

Molly R Braun, Lam-Quynh Nguyen, Becca A Flitter, Nicholas J Bennett, Darreann Carmela M Hailey, Colin A Lester, Elena D Neuhaus, Kirsten Marx, Nick P D'Amato, Kayan Tam and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Molly R BraunVaxart, Inc., South San Francisco, CA, USA. mbraun@vaxart.com.
Lam-Quynh NguyenVaxart, Inc., South San Francisco, CA, USA.
Becca A FlitterVaxart, Inc., South San Francisco, CA, USA.
Nicholas J BennettVaxart, Inc., South San Francisco, CA, USA.
Darreann Carmela M HaileyVaxart, Inc., South San Francisco, CA, USA.
Colin A LesterVaxart, Inc., South San Francisco, CA, USA.
Elena D NeuhausVaxart, Inc., South San Francisco, CA, USA.
Kirsten MarxCenter for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, USA.
Nick P D'AmatoVaxart, Inc., South San Francisco, CA, USA.
Kayan TamVaxart, Inc., South San Francisco, CA, USA.
Marcela F PasettiCenter for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, USA.
Sean N TuckerVaxart, Inc., South San Francisco, CA, USA.
James F CummingsVaxart, Inc., South San Francisco, CA, USA.

Funding

The Bill and Melinda Gates Foundation INV-051351
6 · The paper itself

Abstract

Norovirus can cause severe and potentially fatal gastroenteritis in infants. Mucosal vaccination of breastfeeding women may promote infant protection by enriching antibody responses in consumed breast milk. Here, we report a double-blind, placebo-controlled phase 1 trial in South Africa (SANCTR: DOH-27-072023-7893) to evaluate a single-dose oral bivalent vaccine against norovirus genotypes GI.1 and GII.4 in post-partum breastfeeding women. Safety and reactogenicity (primary outcome), breast milk and serum norovirus-specific antibodies (primary outcome), and passive transfer of antibodies to infants as measured in infant stool (exploratory outcome) were assessed. The vaccine was safe and well tolerated with similar reports of mild or moderate adverse events between placebo (n = 16) and vaccine groups (5 × 10

Identifiers

PMID41530181
PMCPMC12887003

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.